Particulate air pollution, progression, and survival after myocardial infarction.

OBJECTIVE: Several studies have examined the effect of particulate pollution (PM) on survival in general populations, but less is known about susceptible groups. Moreover, previous cohort studies have been cross-sectional and subject to confounding by uncontrolled differences between cities.

DESIGN: We investigated whether PM was associated with progression of disease or reduced survival in a study of 196,000 persons from 21 U.S. cities discharged alive following an acute myocardial infarction (MI), using within-city between-year exposure to PM. We constructed city-specific cohorts of survivors of acute MI using Medicare data between 1985 and 1999, and defined three outcomes on follow-up: death, subsequent MI, and a first admission for congestive heart failure (CHF). Yearly averages of P[M.sub.10] (particulate matter with aerodynamic diameter < 10 [micro]m) were merged to the individual annual follow-up in each city. We applied Cox's proportional hazard regression model in each city, with adjustment for individual risk factors. In the second stage of the analysis, the city-specific results were combined using a meta-regression.

RESULTS: We found significant associations with a hazard ratio for the sum of the distributed lags of 1.3 [95% confidence interval (CI), 1.2-1.5] for mortality, a hazard ratio of 1.4 (95% CI, 1.2-1.7) for a hospitalization for CHF, and a hazard ratio of 1.4 (95% CI, 1.1-1.8) for a new hospitalization for MI per 10 [micro]g/[m.sup.3] P[M.sub.10].

CONCLUSIONS: This is the first long-term study showing a significant association between particle exposure and adverse post-MI outcomes in persons who survived an MI.

KEY WORDS: air pollution, epidemiology, heart diseases, myocardial infarction, survival. Environ Health Perspect 115:769-775 (2007). doi:10.1289/ehp.9201 available via http://dx.doi.org/ [Online 20 February 2007]

**********

Studies have shown short-term effects of particulate pollution (PM) on hospital admissions and deaths from cardiovascular causes (Anderson et al. 2003; Braga et al. 2001; Dockery 2001; Katsouyanni et al. 1996; Pope et al. 2004a; Samet et al. 2000; Schwartz 1999; Zanobetti et al. 2000). Myocardial infarctions (MIs) have been shown to be susceptible to being triggered by PM (Braga et al. 2001; D'Ippoliti et al. 2003; Lanki et al. 2006; Peters et al. 2001a; von Klot et al. 2005; Zanobetti and Schwartz 2005). These studies have not addressed whether persons who survive an MI are at risk of death in response to subsequent particle exposure.

A few studies have addressed this question with respect to acute exposure. For example, Bateson and Schwartz (2004) reported subjects in Chicago who were discharged alive for an MI had twice the risk of death due to acute air pollution exposure as other subjects.

In a recent study of five European cities, von Klot et al. (2005) found that ambient air pollution was associated with increased risk of hospital cardiac readmissions of MI survivors. Peters et al. (2006) examined the probability of recurrent hospitalization in a cohort of MI survivors; compared the use of time-series, case-crossover, and survival analysis for analyzing short-term health effects; and found that the three methods gave similar results. None of these studies examined the effect of longer-term exposure on survival.

Several studies have examined the effect of longer-term PM exposure on survival in general cohorts. The Harvard Six Cities Study (Dockery et al. 1993) demonstrated an association between mortality and chronic exposure to PM. A recent reanalysis of the Harvard Six Cities Study, which extended the mortality follow-up period, used a similar approach to our study and included P[M.sub.2.5] (PM with aerodynamic diameter < 2.5 [micro]m) as a time-varying exposure; Laden et al. (2006) found significant association of P[M.sub.2.5] with mortality.

Two articles (Pope et al. 2002, 2004a) have shown an association between PM and mortality in the American Cancer Society (ACS) Cancer Prevention Study population, including an association between PM and deaths from all cardiovascular disease (Pope et al. 2004a).

These studies have treated air pollution as a city-level variable, whereas two European cohort studies have assessed exposure at an individual level. Hoek et al. (2002) found an association between estimated long-term exposure to traffic-related particles at each participant's home and cause-specific mortality in the Netherlands Cohort Study on Diet and Cancer. Nafstad et al. (2004) found an association between estimated nitrogen dioxide concentrations at the subject's home and the risk of dying for total, respiratory, lung cancer, and ischemic heart disease mortality in a cohort of men in Oslo, Norway. Particle data was not available in that study, and N[O.sub.2] was used as a marker of traffic pollution.

Although these studies have reported an association of PM with survival, they have not evaluated the role of preexisting cardiac disease or whether risk changed with annual changes in exposure, nor have they treated pollution as a time-varying covariate.

Reduced heart rate variability has been associated with decreased survival of MI patients (Ewing 1991; Malik et al. 1989), and PM has been associated with reduced heart rate variability (Creason et al. 2001; Gold et al. 2000; Liao et al. 1999; Park et al. 2005; Pope et al. 1999), which in turn is associated with decreased post-MI survival (Stein et al. 2005). Other studies have suggested that PM may be associated with increased C-reactive protein (Brook et al. 2003; Peters et al. 2001b), which is associated with mortality risk following an MI (Kinjo et al. 2005). PM and its components have also been shown to increase oxidative stress in the heart (Bouthillier et al. 1998; Brook et al. 2003; Dhalla et al. 2000; Sorensen et al. 2003), to decrease plaque stability (Suwa et al. 2002), and to increase atherosclerosis (Kunzli et al. 2005). Based on this, we investigated whether annual PM exposure was associated with progression of disease or reduced survival in a study of 196,000 persons discharged alive following an acute MI.

Materials and Methods

Study population. Using Medicare data for persons [greater than or equal to] 65 years of age, we constructed a cohort of survivors of acute MI, defining cases as emergency admissions for a primary discharge diagnosis of MI [International Classification of Diseases, Ninth Revision (ICD-9; World Health Organization 1975) code 410] discharged alive between 1985 and 1999 in any of 21 cities chosen to represent a broad range of the country. We obtained from Medicare the date of death for each subject, or whether they were still alive as of the end of 1999. We also retrieved information on age, sex, race, and the number of coronary intensive care days and Medical intensive care days.

To study progression of disease, we traced each subject through subsequent Medicare records and identified admissions for a subsequent MI or for congestive heart failure (CHF; ICD-9 code 428).

Subjects alive the first of January of the year following the admission were entered into the cohort, and follow-up periods were calendar years. We excluded subjects whose death or subsequent admission occurred within the first 3 months of their index admission.

We also used a unique identifier for each subject to assess medical factors that might modify the risk of survival or progression, such as whether they had any primary or secondary diagnosis of chronic obstructive pulmonary disease (COPD; ICD-9 codes 490-496, except 493), diabetes (ICD-9 code 250), or essential hypertension (ICD-9 code 401); or if they had previous admissions for atrial fibrillation (ICD-9 code 427.3).

During 1985-1999 changes in treatment occurred, such as introduction of thrombolytics and increased angioplasty. To control for changes in postdischarge survival, we used strata to allow a different underling hazard for each 5-year interval in the study.

We defined a categorical variable for type of MI as given by the fourth digit of the ICD-9 code. There are 10 different types of MI: ICD-9 code 410.0, MI of anterolateral wall; 410.1, other anterior wall; 410.2, inferolateral wall; 410.3, inferoposterior wall; 410.4, other inferior wall; 410.5, other lateral wall; 410.6, true posterior wall infarction; 410.7, subendocardial infarction; 410.8, other specified sites; and 410.9, unspecified sites.

City characteristics, such as population density and percentage of population [greater than or equal to] 65 years of age in poverty status, were obtained from the 1990 U.S. census (U.S. Census Bureau 2000). The average annual mortality rate for emphysema among people [greater than or equal to] 65 years of age during 1989-2000 were obtained from the National Center for Health Statistics (Hyattsville, MD) and used as an indirect measure of smoking history in each city.

The accuracy of the Medicare claims-based diagnosis of MI has been recently validated (Kiyota et al. 2004).

Environmental data. We obtained data for P[M.sub.10] (particulate air matter with aerodynamic diameter < 10 [micro]m) for 1985-1999 from the U.S. Environmental Protection Agency's Aerometric Information Retrieval System (Nehls and Akland 1973).

We selected the following cities with daily P[M.sub.10] monitoring that represent a geographic distribution across the country: Birmingham, Alabama; Boulder, Colorado; Canton, Ohio; Chicago, Illinois; Cincinnati, Ohio; Cleveland, Ohio; Colorado Springs, Colorado; Columbus, Ohio; Denver, Colorado; Detroit, Michigan; Honolulu, Hawaii; Houston, Texas; Minneapolis-St.Paul, Minnesota; Nashville, Tennessee; New Haven, Connecticut; Pittsburgh, Pennsylvania; Provo-Orem, Utah; Salt Lake City, Utah; Seattle, Washington; Steubenville, Ohio; and Youngstown, Ohio.

For most cities, the metropolitan county encompassed the city and much of its suburbs, but we used multiple counties for Minneapolis-St. Paul (Ramsey and Hennepin), Birmingham (Blount, Jefferson, St. Clair, Shelby, and Walker), Steubenville (Jefferson, OH; Brooke and Hancock, WV), and Youngstown (Columbiana and Mahoning).

For each subject and follow-up period we created yearly averages (January-December) of pollution for that year and lags up to the 3 previous years.

Analytical strategy. We defined the cohort as follows: We assumed that a subject admitted for MI enters the cohort if he survived at least 3 months and/or is alive the first January of the year following the admission. For each subject, the follow-up periods were 1 year periods (January-December) until the year in which they die (or suffer a subsequent MI or CHF admission for those analyses) or until December 1999 (censoring).

City-specific cohorts were created for the three survival analyses, one where failure was defined as death, one where failure was defined as a new MI, and one where failure was defined as a first admission for CHF.

We analyzed the data with an extended Cox's proportional hazard regression model, which allows for time-varying covariates in survival analysis (Kleinbaum and Klein 2005). The model for the hazard h at time t is

h[t,X(t)] = [h.sub.0](t) exp[[[SIGMA].sub.i=1 to p1] [[beta].sub.i] [X.sub.i] + [[SIGMA].sub.j=1 to p2] [[delta].sub.j] [Z.sub.j](t)], [1]

where t is time since a subject entered the cohort (January) after the admission for MI and is represented by 1 year; [X.sub.1],... [X.sub.p1] are time-invariant variables such as sex; and [Z.sub.1](t),..., [Z.sub.p2](t) are time-varying variables such as air pollution.

We adjusted for individual risk factors including age, sex, race, type of MI, number of days of coronary care and intensive care, previous diagnoses for atrial fibrillation, and secondary or previous diagnoses for COPD, diabetes, and hypertension, and for season of initial event as cold (December-February), hot (June-August), and transitional. To allow for possible nonproportionality of the survival rates, time period (three categories: 1985-1989, 1990-1994, and 1995-1999), age (5-year categories), sex, race (white, black, others), and type of MI (10 categories) were treated as stratification variables.

Ties were treated using the approach of Kalbfleisch and Prentice (1980).

As a sensitivity analysis, we considered an alternative definition of our follow-up period. We defined yearly follow-up (and exposure averages) using a 12-month period starting the month of their index admission. We continued to construct 12-month average PM exposure for each subject for each subsequent year of follow-up (using month of initial event as the anniversary) until censoring or failure. In the last follow-up period for each subject, the person time at risk was < 12 months, and this was incorporated in the model. However, PM exposure was kept as a 12-month average to maintain comparability with other periods. When the last follow-up period was [less than or equal to] 3 months, subjects were censored at their last complete 12-month period of follow-up because the exposure interval was judged too short to be comparable to the 12-month exposure used for the follow-up periods.

We also restricted the mortality and CHF cohorts to subjects with a second MI, with follow-up beginning after the occurrence of their second MI, or including only those subjects who were admitted for their primary MI between 1985 and 1996, allowing at least 3 years of follow-up to all subjects in the analysis.

For each subject in each follow-up period, we considered the following possible exposure indexes: a) the average P[M.sub.10] in their city in that follow-up period; and b) a model containing simultaneously the exposure during the follow-up period and each of the three previous years (distributed lag), to see if we could determine how the PM dropped off over time.

We first performed city-specific analyses; in the second stage of the analysis, the results were combined using the meta-regression technique of Berkey et al. (1998). To be conservative, we report the results incorporating a random effect, whether or not there was a significant heterogeneity.

Effect modification by individual risk factors was examined by fitting separate proportionate hazard models for each group (e.g., sex) in each city, controlling for covariates and combining across cities as in the main analysis. In addition, we examined effect modification by city characteristics by entering them as predictor variables in the meta-regression. These included measures of socioeconomic condition (percent in poverty), exposure-related measures (mean and interquartile range of P[M.sub.10] in the city), general social factors (population density), and the emphysema death rate in persons [greater than or equal to] 65 years of age as a surrogate for the smoking history of the population. The results are expressed as hazard ratio (HR) for 10 [micro]g/[m.sup.3] P[M.sub.10].

Results

There were 196,131 eligible MIs in the 21 cities during the study period. Table 1 shows characteristics of the study population for all the cities. Of the population, 45.5% died by the end of follow-up, 17% had a CHF admission after the index MI, and 11.5% had a subsequent MI. In the cohort, 63% of the subjects were [greater than or equal to] 75 years of age. The most common types of MI were subendocardial infarction (34%), MI of other inferior wall (23%), and MI of other anterior wall (19%).

The average duration of the follow-up was 5.1 years for mortality, 3.7 years for CHF, and 3.6 years for subsequent MI. The range of survival times in all the cohorts varied from 1 to 14 years.

Table 2 presents city-specific characteristics, including the total population, PM concentrations, counts of hospital admissions for MI, and the numbers of deaths, subsequent acute MI, and first hospitalizations for CHF. The average P[M.sub.10] across all cities was 28.8 [micro]g/[m.sup.3].

Table 3 presents the city-specific incidence rates for the three outcomes. In total, the incidence rates were 0.091 for death, 0.054 for CHF admission, and 0.027 for subsequent MI. The incidence rates among all cities were examined by year (Table 4); these were higher in the first 5 years but changed little during the following years, justifying the use of three categories to describe the time period.

We found significant associations in the three survival analyses adjusting for confounders (Table 5), with a hazard ratio for the sum of the distributed lag for mortality of 1.3 [95% confidence interval (CI), 1.2-1.5] per 10 [micro]g/[m.sup.3] P[M.sub.10], a hazard ratio of 1.4 (95% CI, 1.2-1.7) for CHF, and a hazard ratio of 1.4 (95% CI, 1.1-1.8) per 10 [micro]g/[m.sup.3] P[M.sub.10] for a new hospitalization for MI. The distributed lag model shows greater effects at lags 1 and 2 exposure, with an overall effect considerably larger than for a single year.

Table 6 presents the results of the sensitivity analyses. When we restricted the mortality and CHF analysis to subjects with a second MI with follow-up beginning after the occurrence of their second MI, the effect of P[M.sub.10] for the distributed lag model showed an HR of 1.3 (95% CI, 1.15-1.55) in the mortality cohort and an HR of 1.4 (95% CI, 1.22-1.65) in the CHF cohort. Including only those subjects who were admitted for their primary MI between 1985 and 1996, that is, with at least 3 years of follow-up, we found higher estimates than the main results reported in Table 5.

In Table 6 we also present the result of the sensitivity analysis in which we modified the definition of the cohort. For the distributed lag, we found an HR for mortality of 1.3 (95% CI, 1.15-1.4) per 10 [micro]g/[m.sup.3] P[M.sub.10]; this HR is similar to the main result in Table 5.

Figure 1 shows the results of the analysis of effect modification by sex and age groups (65-75 years of age and [greater than or equal to] 76 years). We did not find effect modification by sex, but we did find a higher effect in the older age group. Following the method of Payton et al. (2003) to determine whether the difference between the age groups was significant, we found a p-value for mortality of 0.064, whereas the p-value for subsequent MI and CHF was 0.082.

We used meta-regression (Berkey et al. 1998) to examine predictors of heterogeneity across city (Table 7), and we found that most of the predictors were not significant as modifiers of the P[M.sub.10] effect.

Discussion

We found a significant effect of long-term exposure to airborne particles on the risk of death, progression to heart failure, and a subsequent MI in a large multicity study of subjects discharged alive following an acute MI. This association was not due to differences between cities in exposure, but resulted from the association of year-to-year changes in mortality risk with year-to-year changes in exposure. We found that association persisted for several years of lag, but was falling off by lag 3.

Although several previous studies have reported an association of PM with mortality in survival analysis, this is the first long-term study that investigated persons discharged alive following an acute MI and showed that persons who survive an MI are at risk of death in response to subsequent particle exposure. The present study is the first large cohort study focused on the elderly.

One key difference between the present study and previous cohorts comes from the source of variation in exposure. In the other cohort studies, the source of exposure variation is across geographic area. For example, the ACS study (Pope et al. 2004a) contrasted covariate-adjusted survival in each city with long-term average pollution in that city. Using such an approach, unmeasured factors that vary across city are potential confounders. For example, substantial geographic variability in the use of cardiovascular medication has been reported in a number of studies, and this was not controlled in previous cohort studies. In the present study the basic analysis was conducted within each city, and exposure variation comes from temporal changes in pollution concentration. This eliminates those potential confounders as a concern. By focusing on 12-month average exposures, it also eliminates the potential confounding by short-term weather factors that are an issue in time-series studies. Obviously, factors that fluctuate from year to year within each city are potential confounders in this study design. The advantage of this approach is that it allows us to use an analytical methodology with different vulnerabilities to confounding than in previous studies; to determine whether an association between PM and mortality risk persists; and to examine an intermediate time period of exposure--in contrast to the use of daily exposure in time-series studies--and exposure over many years in other cohorts.

The use of longitudinal rather than cross-sectional exposure gradients in this study may also explain some of the differences in effect size estimates, because the variation in central station monitoring and personal exposure over time may be more correlated than similar variations over space. Moreover, the ACS study (Pope et al. 2004a) used monitors within the multicounty metropolitan areas to assign exposure, whereas our subjects are matched to monitors in the same city or county. A recent reanalysis of ACS data restricting to persons living in the same county of the monitor reported a larger risk (Pope et al. 2004a; Willis et al. 2003).

The sensitivity analysis in the present study showed that subjects with a second MI have a higher risk of a PM-associated subsequent death. Hence, this appears to represent a particularly susceptible group.

In a recent case-crossover study examining this association, Bateson and Schwartz (2004) reported much smaller relative risks (1.02; 95% CI, 0.99-1.04). In another case-crossover study (Zanobetti and Schwartz 2005) on 21 U.S. cities, we analyzed the short-term effect of P[M.sub.10] on the MI hospitalization in these cities. In that analysis, we also found a smaller relative risk (1.007; 95% CI, 1.003-1.01). Although part of the association reported here may be acute, the evidence indicates cumulative exposure over a year or more elevates risk above and beyond the effects of acute exposure.

We observed a high degree of heterogeneity among the cities. In multicities time-series studies of short-term effect of air pollution on health, heterogeneity has been found among cities (Katsouyanni et al. 2001; Le Tertre et al. 2002; Samet et al. 2000). Heterogeneity has been attributed to, for example, differences in particle characteristics, ventilation rates of buildings, average P[M.sub.10] concentrations, and social conditions. Previously published cohort studies could not address the issue of heterogeneity because the studies were essentially cross-sectional; the source of exposure variation was across geographic area. This is the first long-term study to show significant heterogeneity among cities in response to long-term exposure, and the cause of this heterogeneity needs to be determined.

This analysis advances the field a) by reporting an association between particle exposure and survival in a cohort study of MI survivors that eliminates geographic variation in risk factors as a confounder, but where exposure variation comes from temporal changes in pollution concentration; and b) by focusing on associations on an intermediate time scale. If PM increases progression of atherosclerosis (Kunzli et al. 2005; Suwa et al. 2002) or impairs endothelial function (Brook et al. 2004) or autonomic function (Liao et al. 1999; O'Neill et al. 2005), these changes may have greater impact in populations with greater underlying impairment, such as the elderly.

A primary candidate for explaining these risks must be the acute MI itself (Berger et al. 1992; Guidry et al. 1999; Kannel et al. 1979). Subjects surviving MIs have enhanced risk of dying and decreased heart rate variability (Malik et al. 1989), and are likely to have greater susceptibility to subsequent insults.

This possibility of multiple pathways to mortality makes it plausible that the all-cause mortality risk might exceed the risk of specific cardiac events, as we observe for subsequent MI. For example, PM has been associated with arrhythmias (Peters et al. 2000), pneumonia (Zanobetti et al. 2000), and COPD (Schwartz 1993), creating potential additional pathways by which exposure could increase mortality risk independent of MI risk.

One limitation of the present study is that Medicare does not provide the underlying cause of death. If the cause of death were available, we could understand better the possible pathways.

Future studies examining cohorts with more detailed clinical data on the MI survivors should be fruitful. The increased risk of heart failure following the MI also suggests that further evaluation of this outcome is warranted.

The present study presents additional limitations, the main one being the absence of information on subject characteristics such as smoking, body mass index, or medicine use, and information on whether the patients migrated out of the study areas after their last Medicare contact. However, we were able to adjust for other important characteristics such as age, race, sex, the type of MI, and previous and secondary diagnoses. Missing those other characteristics would only confound the association with air pollution if they were correlated with pollution. However, we conducted a city-specific analysis to remove location-specific differences in the analyses. Hence, differences across cities in smoking rates, for example, cannot confound the association, because only the temporal variability in pollution within city contributes to the association. Smoking could only confound this association if year-to-year variations in smoking rates within city covaried with year-to-year variations in P[M.sub.10] concentrations. Moreover, we examined the emphysema death rate in persons > 65 years of age as an effect modifier because it is associated with smoking history in the population, and found that it did not modify the PM-associated risk. Thus, smoking is unlikely to be a confounder in our study.

Our findings that both subsequent MIs and CHF admissions, as well as mortality risk, are elevated suggests that multiple pathways are involved in the particle effects.

Other human and animal studies (Godleski et al. 2000) have shown associations between particulate pollution and changes in heart rate variability (Gold et al. 2000; Liao et al. 1999; Pope et al. 1999); increases in plasma viscosity (Peters et al. 1997), C-reactive protein (Brook et al. 2003; Peters et al. 2001b; Pope et al. 2004b), plasma fibrinogen (Ghio et al. 2000), white blood cell counts (Salvi et al. 1999; Schwartz 2001), blood pressure (Ibald-Mulli et al. 2001; Linn et al. 1999; Zanobetti et al. 2004), and oxidative stress (Bouthillier et al. 1998; Brook et al. 2003; Sorensen et al. 2003); decreases in plaque stability (Suwa et al. 2002); or occurrence of thrombotic complications after exposure to pollutants (Nemmar et al. 2003). In a recent study O'Neill et al. (2005) reported that PM was associated with flow-mediated dilation of the brachial arteries.

Many of these associations are with acute exposure, not long-term exposures such as those used in the present study. Nevertheless, the associations suggest that the hypotheses to explain the potential mechanisms for the particle effects might involve systemic inflammation, changes in autonomic function, or oxidative stress capable of influencing both cardiovascular and pulmonary physiology.

Our findings suggest that persons surviving an MI are at risk from exposure to particulate pollution. This is a large group, and hence this finding has substantial public health implications. Our results also suggest that it would be beneficial to examine this population in mechanistic studies.

REFERENCES

Anderson HR, Atkinson RW, Bremner SA, Marston L. 2003. Particulate air pollution and hospital admissions for cardiorespiratory diseases: are the elderly at greater risk? Eur Respir J Suppl 40:39s-46s.

Bateson TF, Schwartz J. 2004. Who is sensitive to the effects of particulate air pollution on mortality? A case-crossover analysis of effect modifiers. Epidemiology 15:143-149.

Berger CJ, Murabito JM, Evans JC, Anderson KM, Levy D. 1992. Prognosis after first myocardial infarction. Comparison of Q-wave and non-Q-wave myocardial infarction in the Framingham Heart Study. JAMA 268:1545-1551.

Berkey CS, Hoaglin DC, Antczak-Bouckoms A, Mosteller F, Colditz GA. 1998. Meta-analysis of multiple outcomes by regression with random effects. Stat Med 17:2537-2550.

Bouthillier L, Vincent R, Goegan P, Adamson IY, Bjarnason S, Stewart M, et al. 1998. Acute effects of inhaled urban particles and ozone: lung morphology, macrophage activity, and plasma endothelin-1. Am J Pathol 153:1873-1884.

Braga AL, Zanobetti A, Schwartz J. 2001. The lag structure between particulate air pollution and respiratory and cardiovascular deaths in 10 US cities. J Occup Environ Med 43:927-933.

Brook RD, Brook JR, Rajagopalan S. 2003. Air pollution: the "heart" of the problem. Curr Hypertens Rep 5:32-39.

Brook RD, Franklin B, Cascio W, Hong Y, Howard G, Lipsett M, et al. 2004. Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association. Circulation 109:2655-2671.

Creason J, Neas L, Walsh D, Williams R, Sheldon L, Liao D, et al. 2001. Particulate matter and heart rate variability among elderly retirees: the Baltimore 1998 PM study. J Expo Anal Environ Epidemiol 11:116-122.

Dhalla NS, Temsah RM, Netticadan T. 2000. Role of oxidative stress in cardiovascular diseases. J Hypertens 18:655-673.

D'Ippoliti D, Forastiere F, Ancona C, Agabiti N, Fusco D, Michelozzi P, et al. 2003. Air pollution and myocardial infarction in Rome: a case-crossover analysis. Epidemiology 14:528-535.

Dockery DW. 2001. Epidemiologic evidence of cardiovascular effects of particulate air pollution. Environ Health Perspect 109:483-486.

Dockery DW, Pope CA III, Xu X, Spengler JD, Ware JH, Fay ME, et al. 1993. An association between air pollution and mortality in six U.S. Cities. N Engl J Med 329:1753-1759.

Ewing DJ. 1991. Heart rate variability: an important new risk factor in patients following myocardial infarction. Clin Cardiol 14:683-685.

Ghio AJ, Kim C, Devlin RB. 2000. Concentrated ambient air particles induce mild pulmonary inflammation in healthy human volunteers. Am J Respir Crit Care Med 162:981-988.

Godleski JJ, Verrier RL, Koutrakis P, Catalano P, Coull B, Reinisch U, et al. 2000. Mechanisms or morbidity and mortality from exposure to ambient air particles. Res Rep Health Eff Inst 91:5-88.

Gold DR, Litonjua A, Schwartz J, Lovett E, Larson A, Nearing B, et al. 2000. Ambient pollution and heart rate variability. Circulation 101:1267-1273.

Guidry UC, Evans JC, Larson MG, Wilson PW, Murabito JM, Levy D. 1999. Temporal trends in event rates after Q-wave myocardial infarction: the Framingham Heart Study. Circulation 100:2054-2059.

Hoek G, Brunekreef B, Goldbohm S, Fischer P, van den Brandt PA. 2002. Association between mortality and indicators of traffic-related air pollution in the Netherlands: a cohort study. Lancet 360:1203-1209.

Ibald-Mulli A, Stieber J, Wichmann HE, Koenig W, Peters A. 2001. Effects of air pollution on blood pressure: a population-based approach. Am J Public Health 91:571-577.

Kalbfleisch JD, Prentice RL. 1980. The Statistical Analysis of Failure Time Data. New York:John Wiley & Sons.

Kannel WB, Sorlie P, McNamara PM. 1979. Prognosis after initial myocardial infarction: the Framingham Study. Am J Cardiol 44:53-59.

Katsouyanni K, Schwartz J, Spix C, Touloumi G, Zmirou D, Zanobetti A, et al. 1996. Short term effects of air pollution on health: a European approach using epidemiologic time series data: the APHEA protocol. J Epidemiol Community Health 50(suppl 1):S12-18.

Katsouyanni K, Touloumi G, Samoli E, Gryparis A, Le Tertre A, Monopolis Y, et al. 2001. Confounding and effect modification in the short-term effects of ambient particles on total mortality: results from 29 European cities within the APHEA2 Project. Epidemiology 12:521-531.

Kinjo K, Sato H, Sakata Y, Nakatani D, Mizuno H, Shimizu M, et al. 2005. Relation of c-reactive protein and one-year survival after acute myocardial infarction with versus without statin therapy. Am J Cardiol 96:617-621.

Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. 2004. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 148:99-104.

Kleinbaum DG, Klein M. 2005. Survival analysis. A self-learning text. 2nd ed. New York:Springer.

Kunzli N, Jerrett M, Mack WJ, Beckerman B, LaBree L, Gilliland F, et al. 2005. Ambient air pollution and atherosclerosis in Los Angeles. Environ Health Perspect 113:201-206.

Laden F, Schwartz J, Speizer FE, Dockery DW. 2006. Reduction in fine particulate air pollution and mortality: extended follow-up of the Harvard Six Cities Study. Am J Respir Crit Care Med 173:667-672.

Lanki T, Pekkanen J, Aalto P, Elosua R, Berglind N, D'Ippoliti D, et al. 2006. Associations of traffic-related air pollutants with hospitalisation for first acute myocardial infarction. The HEAPSS Study. Occup Environ Med 63(12):844-851.

Le Tertre A, Medina S, Samoli E, Forsberg B, Michelozzi P, Boumghar A, et al. 2002. Short-term effects of particulate air pollution on cardiovascular diseases in eight European cities. J Epidemiol Community Health 56:773-779.

Liao D, Creason J, Shy C, Williams R, Watts R, Zweidinger R. 1999. Daily variation of particulate air pollution and poor cardiac autonomic control in the elderly. Environ Health Perspect 107:521-525.

Linn WS, Gong H Jr., Clark KW, Anderson KR. 1999. Day-to-day particulate exposures and health changes in Los Angeles area residents with severe lung disease. J Air Waste Manage Assoc 49:108-115.

Malik M, Farrell T, Cripps T, Camm AJ. 1989. Heart rate variability in relation to prognosis after myocardial infarction: selection of optimal processing techniques. Eur Heart J 10:1060-1074.

Nafstad P, Haheim LL, Wisloff T, Gram F, Oftedal B, Holme I, et al. 2004. Urban air pollution and mortality in a cohort of Norwegian men. Environ Health Perspect 112:610-615.

Nehls GJ, Akland GG. 1973. Procedures for handling aerometric data. J Air Pollut Control Assoc 23:180-184.

Nemmar A, Hoet PH, Dinsdale D, Vermylen J, Hoylaerts MF, Nemery B. 2003. Diesel exhaust particles in lung acutely enhance experimental peripheral thrombosis. Circulation 107:1202-1208.

O'Neill MS, Veves A, Zanobetti A, Sarnat JA, Gold DR, Economides PA, et al. 2005. Diabetes enhances vulnerability to particulate air pollution-associated impairment in vascular reactivity and endothelial function. Circulation 111:2913-2920.

Park SK, O'Neill MS, Vokonas PS, Sparrow D, Schwartz J. 2005. Effects of air pollution on heart rate variability: the VA Normative Aging Study. Environ Health Perspect 113:304-309.

Payton ME, Greenstone MH, Schenker N. 2003. Overlapping confidence intervals or standard error intervals: what do they mean in terms of statistical significance? J Insect Sci 3-34.

Peters A, Dockery DW, Muller JE, Mittleman MA. 2001a. Increased particulate air pollution and the triggering of myocardial infarction. Circulation 103:2810-2815.

Peters A, Doring A, Wichmann HE, Koenig W. 1997. Increased plasma viscosity during an air pollution episode: a link to mortality? Lancet 349:1582-1587.

Peters A, Frohlich M, Doring A, Immervoll T, Wichmann HE, Hutchinson WL, et al. 2001b. Particulate air pollution is associated with an acute phase response in men; results from the MONICA-Augsburg Study. Eur Heart J 22:1198-1204.

Peters A, Liu E, Verrier RL, Schwartz J, Gold DR, Mittleman M, et al. 2000. Air pollution and incidence of cardiac arrhythmia. Epidemiology 11:11-17.

Peters A, von Klot S, Berglind N, Hormann A, Lowel H, Nyberg F, et al. 2006. Comparison of different methods in analyzing short-term air pollution effects in a cohort study of susceptible individuals. Epidemiol Perspect Innov 3:10; doi:10.1186/1742-5573-3-10 [Online 9 August 2006].

Pope CA III, Burnett RT, Thun MJ, Calle EE, Krewski D, Ito K, et al. 2002. Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA 287:1132-1141.

Pope CA III, Burnett RT, Thurston GD, Thun MJ, Calle EE, Krewski D, et al. 2004a. Cardiovascular mortality and long-term exposure to particulate air pollution: epidemiological evidence of general pathophysiological pathways of disease. Circulation 109:71-77.

Pope CA III, Hansen ML, Long RW, Nielsen KR, Eatough NL, Wilson WE, et al. 2004b. Ambient particulate air pollution, heart rate variability, and blood markers of inflammation in a panel of elderly subjects. Environ Health Perspect 112:339-345.

Pope CA III, Verrier RL, Lovett EG, Larson AC, Raizenne ME, Kanner RE, et al. 1999. Heart rate variability associated with particulate air pollution. Am Heart J 138:890-899.

Salvi S, Blomberg A, Rudell B, Kelly F, Sandstrom T, Holgate ST, et al. 1999. Acute inflammatory responses in the airways and peripheral blood after short-term exposure to diesel exhaust in healthy human volunteers. Am J Respir Crit Care Med 159:702-709.

Samet JM, Zeger SL, Dominici F, Curriero F, Coursac I, Dockery DW, et al. 2000. The National Morbidity, Mortality, and Air Pollution Study. Part II: morbidity and mortality from air pollution in the United States. Res Rep Health Eff Inst 94:5-70.

Schwartz J. 1993. Particulate air pollution and chronic respiratory disease. Environ Res 62:7-13.

Schwartz J. 1999. Air pollution and hospital admissions for heart disease in eight U.S. Counties. Epidemiology 10:17-22.

Schwartz J. 2001. Air pollution and blood markers of cardiovascular risk. Environ Health Perspect 109:405-409.

Sorensen M, Daneshvar B, Hansen M, Dragsted LO, Hertel O, Knudsen L, et al. 2003. Personal PM2.5 exposure and markers of oxidative stress in blood. Environ Health Perspect 111:161-166.

Stein PK, Domitrovich PP, Huikuri HV, Kleiger RE. 2005. Traditional and nonlinear heart rate variability are each independently associated with mortality after myocardial infarction. J Cardiovasc Electrophysiol 16:13-20.

Suwa T, Hogg JC, Quinlan KB, Ohgami A, Vincent R, van Eeden SF. 2002. Particulate air pollution induces progression of atherosclerosis. J Am Coll Cardiol39:935-942.

U.S. Census Bureau. 2000. 1990 Decennial Census of Population and Housing Characteristics. Washington, DC:Department of Housing and Urban Development.

Von Klot S, Peters A, Aalto P, Bellander T, Berglind N, D'Ippoliti D, et al. 2005. Ambient air pollution is associated with increased risk of hospital cardiac readmissions of myocardial infarction survivors in five European cities. Circulation 112:3073-3079.

Willis A, Jerrett M, Burnett RT, Krewski D. 2003. The association between sulfate air pollution and mortality at the county scale: an exploration of the impact of scale on a long-term exposure study. J Toxicol Environ Health A 66:1605-1624.

World Health Organization. 1975. International Classification of Diseases, Ninth Revision. Geneva:World Health Organization.

Zanobetti A, Canner MJ, Stone PH, Schwartz J, Sher D, Eagan-Bengston E, et al. 2004. Ambient pollution and blood pressure in cardiac rehabilitation patients. Circulation 110:2184-2189.

Zanobetti A, Schwartz J. 2005. The effect of particulate air pollution on emergency admissions for myocardial infarction: a multicity case-crossover analysis. Environ Health Perspect 113:978-982.

Zanobetti A, Schwartz J, Dockery DW. 2000. Airborne particles are a risk factor for hospital admissions for heart and lung disease. Environ Health Perspect 108:1071-1077.

Antonella Zanobetti and Joel Schwartz

Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA

Address correspondence to A. Zanobetti, Department of Environmental Health, Exposure Epidemiology and Risk Program, Harvard School of Public Health, 401 Park Dr., Landmark Center, Suite 415, P.O. Box 15698, Boston, MA 02215 USA. Telephone: [phone]. Fax: [phone]. E-mail: [e-mail]

This study was supported by the U.S. Environmental Protection Agency (EPA)/Harvard Center on Ambient Particle Health Effects EPA PM Center (U.S. EPA grant R827353).

The authors declare they have no competing financial interests.

Received 25 March 2006; accepted 20 February 2007.

Table 1. Characteristics of the study population among residents of 21
U.S. cities.

                                                            Mean
                                                            (5th-95th
Characteristic                      No. of events  Percent  percentiles)

MI                                  196,131
Failure
  Deaths                             89,249        45.5
  CHF                                33,764        17.2
  Subsequent MI                      22,552        11.5
Baseline characteristics
  Age                                                       76.1 (66.5-
                                                              89.1)
  Sex
    Male                             98,822        50.4
    Female                           97,309        49.6
  Race
    White                           165,549        84.4
    Black                            19,759        10.1
    Other                            10,823         5.5
  No. of days in coronary care                               1.3 (0-6.5)
  No. of days in intensive care                              1.5 (0-6.5)
  Type of MI
    Anterolateral wall               10,088         5.1
    Other anterior wall              37,993        19.4
    Inferolateral wall                6,434         3.3
    Inferoposterior wall              4,291         2.2
    Other inferior wall              44,923        22.9
    Other lateral wall                5,326         2.7
    True posterior wall infarction    2,009         1.0
    Subendocardial infarction        66,628        34.0
    Other specified sites             3,951         2.0
    Unspecified sites                14,488         7.4
  Secondary or previous diagnoses
    COPD                             28,509        14.5
    Diabetes                         44,686        22.8
    Hypertension                     72,154        36.8
  Previous admissions
    Atrial fibrillation              11,374         5.8

Table 2. City-specific counts of hospital admissions for MI, second MI,
first CHF, and deaths and for distribution of P[M.sub.10].

                      MI                  CHF     2nd MI
City                  admissions  Deaths  events  events

Birmingham, AL         8,927       4,281  1,814   1,028
Boulder, CO            1,117         434    176      97
Canton, OH             4,788       2,061    797     594
Chicago, IL           42,091      20,333  7,673   5,130
Cincinnati, OH         7,961       3,778  1,381     906
Cleveland, OH         16,648       7,767  3,140   1,899
Colorado Springs, CO   2,054         672    282     173
Columbus, OH           7,859       3,574  1,370   1,044
Denver, CO             3,919       1,551    546     357
Detroit, MI           18,437       8,490  3,439   2,098
Honolulu, HI           4,528       1,952    633     484
Houston, TX           10,885       4,764  1,812     975
Minneapolis, MN       10,123       3,962  1,360   1,019
Nashville, TN          4,081       1,877    697     449
New Haven, CT          9,232       4,245  1,447   1,119
Pittsburg, PA         20,663      10,007  3,653   2,800
Provo/Orem, UT         1,504         535    258     136
Salt Lake City, UT     3,535       1,233    425     256
Seattle, WA            9,674       4,011  1,325     921
Steubenville, OH       2,502       1,130    499     302
Youngstown, OH         5,603       2,592  1,037     765

                      No.
                      [greater than or equal to]65  P[M.sub.10] (a) %
City                  years of age (b)              10    50    90

Birmingham, AL        120                           22.8  27.0  38.2
Boulder, CO            17                           18.0  20.6  28.9
Canton, OH             53                           22.1  25.2  28.4
Chicago, IL           632                           29.5  33.4  38.5
Cincinnati, OH        115                           25.5  30.7  38.2
Cleveland, OH         221                           35.2  37.6  42.5
Colorado Springs, CO   32                           18.4  21.0  24.9
Columbus, OH           92                           25.6  28.5  31.6
Denver, CO             64                           26.6  28.9  36.5
Detroit, MI           264                           28.0  31.3  37.9
Honolulu, HI           91                           14.8  16.3  18.7
Houston, TX           196                           26.0  29.7  32.3
Minneapolis, MN       176                           22.3  24.7  31.8
Nashville, TN          59                           27.1  30.2  38.5
New Haven, CT         118                           22.2  24.0  29.3
Pittsburg, PA         233                           25.2  29.5  34.3
Provo/Orem, UT         18                           26.3  32.4  38.5
Salt Lake City, UT     61                           28.2  34.1  43.3
Seattle, WA           167                           16.0  22.6  31.7
Steubenville, OH       24                           26.4  33.9  37.7
Youngstown, OH         61                           27.2  29.2  33.3

(a) Distribution of the individually assigned 1-year P[M.sub.10] mean in
each city. (b) Population [greater than or equal to] 65 years of age
(x 1,000).

Table 3. Accrued person-time and incidence rate for the three survival
analyses.

                      Person-years
City                  Deaths   CHF      2nd MI

Birmingham, AL         44,672   28,995   39,495
Boulder, CO             6,292    4,014    5,305
Canton, OH             23,826   15,333   20,336
Chicago, IL           207,151  125,216  180,216
Cincinnati, OH         39,967   25,530   35,255
Cleveland, OH          83,790   52,392   72,310
Colorado Springs, CO   10,475    7,813    9,430
Columbus, OH           37,725   24,977   33,535
Denver, CO             22,424   15,187   20,178
Detroit, MI            87,612   55,024   74,111
Honolulu, HI           21,831   14,842   19,632
Houston, TX            52,910   36,734   46,250
Minneapolis, MN        51,318   34,124   46,421
Nashville, TN          20,710   14,039   18,168
New Haven, CT          46,935   28,516   40,926
Pittsburg, PA         101,145   63,399   82,726
Provo/Orem, UT          8,138    5,401    6,798
Salt Lake City, UT     19,021   13,236   17,136
Seattle, WA            52,168   34,519   46,465
Steubenville, OH       11,674    6,986    9,311
Youngstown, OH         27,146   16,902   23,182
Total                 976,930  623,179  847,186

                      Incidence rate
City                  Deaths  CHF    2nd MI

Birmingham, AL        0.120   0.063  0.026
Boulder, CO           0.084   0.044  0.018
Canton, OH            0.108   0.052  0.029
Chicago, IL           0.123   0.061  0.028
Cincinnati, OH        0.118   0.054  0.026
Cleveland, OH         0.116   0.060  0.026
Colorado Springs, CO  0.080   0.036  0.018
Columbus, OH          0.120   0.055  0.031
Denver, CO            0.084   0.036  0.018
Detroit, MI           0.123   0.063  0.028
Honolulu, HI          0.113   0.043  0.025
Houston, TX           0.113   0.049  0.021
Minneapolis, MN       0.096   0.040  0.022
Nashville, TN         0.113   0.050  0.025
New Haven, CT         0.113   0.051  0.027
Pittsburg, PA         0.124   0.058  0.034
Provo/Orem, UT        0.081   0.048  0.020
Salt Lake City, UT    0.080   0.032  0.015
Seattle, WA           0.094   0.038  0.020
Steubenville, OH      0.123   0.071  0.032
Youngstown, OH        0.120   0.061  0.033
Total                 0.091   0.054  0.027

Table 4. Accrued person-years, number of deaths, and incidence rate (IR)

across all cities by year for the mortality cohort.

Year  Person-years  No. of deaths  IR

1986   10,015        1,423         0.142
1987   22,094        2,808         0.127
1988   32,640        3,675         0.113
1989   41,852        4,173         0.100
1990   50,173        4,786         0.095
1991   59,419        5,581         0.094
1992   67,713        6,223         0.092
1993   76,769        6,711         0.087
1994   85,574        7,709         0.090
1995   93,209        8,427         0.090
1996  100,260        8,803         0.088
1997  107,150        9,152         0.085
1998  113,019        9,617         0.085
1999  117,043       10,161         0.087

Table 5. HR and 95% CI for 10-[micro]g/[m.sup.3] increase in P[M.sub.10]
for the year of failure and for the distributed lag from the year of
failure up to 3 previous years.

Failure                  HR    95% CI     p-Values

Death
  P[M.sub.10] annual     1.11  1.05-1.19  0.001
  Distributed lag model
    Lag 0                1.04  0.96-1.14  0.336
    Lag 1                1.07  0.99-1.14  0.070
    Lag 2                1.14  1.10-1.18  0.000
    Lag 3                1.06  0.99-1.12  0.077
    Sum lags 0-3         1.34  1.17-1.52  0.000
CHF
  P[M.sub.10] annual     1.11  1.03-1.21  0.009
  Distributed lag model
    Lag 0                1.09  1.01-1.18  0.030
    Lag 1                1.09  1.01-1.19  0.038
    Lag 2                1.13  1.02-1.25  0.014
    Lag 3                1.04  0.97-1.12  0.260
    Sum lags 0-3         1.41  1.19-1.66  0.000
Second MI
  P[M.sub.10] annual     1.17  1.05-1.31  0.003
  Distributed lag model
    Lag 0                1.09  0.92-1.30  0.325
    Lag 1                1.12  0.97-1.30  0.108
    Lag 2                1.15  1.08-1.23  0.000
    Lag 3                1.01  0.94-1.09  0.783
    Sum lags 0-3         1.43  1.12-1.82  0.005

Models controlled for season, days of coronary care and intensive care,
previous diagnosis for atrial fibrillation, and secondary or previous
diagnoses for COPD, diabetes, and hypertension; we adjusted for time
period, age, sex, race, and type of MI as stratification variables.

Table 6. HR and 95% CI for 10 [micro]g/[m.sup.3] increase in P[M.sub.10]
(sum of previous 3 years distributed lag) for the sensitivity analyses.

                                   HR    95% CI     p-Values

Death
  Subjects with subsequent MI (a)  1.33  1.15-1.55  0.000
  Subjects admitted between 1985   1.45  1.26-1.68  0.000
    and 1996 (b)
  Second definition of cohort (c)  1.29  1.15-1.44  0.000
CHF
  Subjects with subsequent MI (a)  1.42  1.22-1.65  0.000
  Subjects admitted between 1985   1.51  1.26-1.81  0.000
    and 1996 (b)
Subsequent MI
  Subjects admitted between 1985   1.62  1.23-2.13  0.001
    and 1996 (b)

(a) Follow-up started after subsequent MI. (b) Includes only primary
admission for MI during 1985 and 1996. (c) Yearly follow-up and 12-month
average P[M.sub.10] exposure for each subject for each subsequent year
of follow-up starting from the month of the index admission until
censoring or failure.

Table 7. Modification of the P[M.sub.10] association in the three
survival analyses by city characteristics across 21 U.S. cities
expressed as HR and 95% CI for 10-[micro]g/[m.sup.3] increase in
P[M.sub.10] (distributed lag) estimated at the 25th percentile and the
75th percentile of the effect modifier.

City            p-Value       HR at the 25% percentile
characteristic  for modifier  1st quartile  HR    95% CI

Population [greater than or equal to] 65 years of age in poverty status
(%)
  Death         0.60            8.0         1.34  1.06-1.70
  CHF           0.83                        1.36  1.05-1.75
  MI            0.61                        1.29  0.91-1.82

Annual mortality rate for emphysema [greater than or equal to] 65 years
of age
  Death         0.57           32.9         1.33  1.07-1.67
  CHF           0.37                        1.42  1.12-1.79
  MI            0.97                        1.26  0.91-1.73

Mean P[M.sub.10]
  Death         0.60           25.5         1.25  1.01-1.55
  CHF           0.74                        1.36  1.08-1.72
  MI            0.04                        1.02  0.76-1.37

IQR P[M.sub.10]
  Death         0.70            3.3         1.31  1.07-1.62
  CHF           0.38                        1.40  1.12-1.74
  MI            0.28                        1.12  0.83-1.50

Population density
  Death         0.67          594.8         1.33  1.06-1.67
  CHF           0.75                        1.30  1.02-1.66
  MI            0.74                        1.17  0.84-1.64

City            p-Value       HR at the 75% percentile
characteristic  for modifier  3rd quartile  HR    95% CI

Population [greater than or equal to] 65 years of age in poverty status
(%)
  Death         0.60            11.4        1.27  1.05-1.53
  CHF           0.83                        1.32  1.08-1.62
  MI            0.61                        1.19  0.91-1.56

Annual mortality rate for emphysema [greater than or equal to] 65 years
of age
  Death         0.57            47.6        1.27  1.04-1.54
  CHF           0.37                        1.30  1.06-1.60
  MI            0.97                        1.25  0.94-1.66

Mean P[M.sub.10]
  Death         0.60            32.1        1.33  1.07-1.65
  CHF           0.74                        1.30  1.03-1.64
  MI            0.04                        1.43  1.08-1.91

IQR P[M.sub.10]
  Death         0.70             5.5        1.26  1.02-1.56
  CHF           0.38                        1.26  1.01-1.58
  MI            0.28                        1.33  0.98-1.79

Population density
  Death         0.67          2076.9        1.27  1.05-1.54
  CHF           0.75                        1.35  1.10-1.65
  MI            0.74                        1.23  0.93-1.62

IQR, interquartile range.